A 16 Week Multi-Center, Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Valsartan/Hydrochlorothiazide (HCTZ) Combination Therapy Compared to Patients Initiated With Valsartan Monotherapy or Hydrochlorothiazide Monotherapy in Very Elderly Patients With Essential Hypertension.

Trial Profile

A 16 Week Multi-Center, Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Valsartan/Hydrochlorothiazide (HCTZ) Combination Therapy Compared to Patients Initiated With Valsartan Monotherapy or Hydrochlorothiazide Monotherapy in Very Elderly Patients With Essential Hypertension.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Aug 2011

At a glance

  • Drugs Hydrochlorothiazide; Valsartan; Valsartan/hydrochlorothiazide
  • Indications Essential hypertension; Hypertension
  • Focus Therapeutic Use
  • Acronyms VALVET
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 21 Jun 2010 Results presented at the 20th European Meeting on Hypertension
    • 21 Jun 2010 Results presented at the 20th European Meeting on Hypertension.
    • 21 Jun 2010 Results presented at the 20th European Meeting on Hypertension.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top